uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
The Clinical Pharmacogenomics Implementation Consortium: CPIC Guideline for SLCO1B1 and Simvastatin-Induced Myopathy
Show others and affiliations
2012 (English)In: Clinical Pharmacology and Therapeutics, ISSN 0009-9236, E-ISSN 1532-6535, Vol. 92, no 1, 112-117 p.Article in journal (Refereed) Published
Abstract [en]

Cholesterol reduction from statin therapy has been one of the greatest public health successes in modern medicine. Simvastatin is among the most commonly used prescription medications. A non-synonymous coding single-nucleotide polymorphism (SNP), rs4149056, in SLCO1B1 markedly increases systemic exposure to simvastatin and the risk of muscle toxicity. This guideline explores the relationship between rs4149056 (c.521T>C, p.V174A) and clinical outcome for all statins. The strength of the evidence is high for myopathy with simvastatin. We limit our recommendations accordingly.

Place, publisher, year, edition, pages
2012. Vol. 92, no 1, 112-117 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-177563DOI: 10.1038/clpt.2012.57ISI: 000305589800019OAI: oai:DiVA.org:uu-177563DiVA: diva2:541282
Available from: 2012-07-16 Created: 2012-07-16 Last updated: 2016-02-19

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Wadelius, Mia
By organisation
Clinical pharmacogenomics and osteoporosis
In the same journal
Clinical Pharmacology and Therapeutics
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 169 hits
ReferencesLink to record
Permanent link

Direct link